Viatris Keeping Powder Dry On Symbicort With Key Ruling Imminent
US-Based Firm Facing Second Suit With November Trial Scheduled
In the coming days, Viatris expects to hear back from a court in West Virginia over its legal tussle with AstraZeneca on Symbicort IP. The US-based player has intimated that it may launch the product dependent on the court’s verdict.
